López-Posadas Rocío, Bagley Dustin C, Pardo-Pastor Carlos, Ortiz-Zapater Elena
Department of Medicine 1, University Hospital of Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Deutsches Zentrum für Immuntherapie, Friedrich-Alexander-Universtiy Eralngen-Nürnberg, Erlangen, Germany.
Front Cell Dev Biol. 2024 Mar 11;12:1258859. doi: 10.3389/fcell.2024.1258859. eCollection 2024.
The epithelium is a dynamic barrier and the damage to this epithelial layer governs a variety of complex mechanisms involving not only epithelial cells but all resident tissue constituents, including immune and stroma cells. Traditionally, diseases characterized by a damaged epithelium have been considered "immunological diseases," and research efforts aimed at preventing and treating these diseases have primarily focused on immuno-centric therapeutic strategies, that often fail to halt or reverse the natural progression of the disease. In this review, we intend to focus on specific mechanisms driven by the epithelium that ensure barrier function. We will bring asthma and Inflammatory Bowel Diseases into the spotlight, as we believe that these two diseases serve as pertinent examples of epithelium derived pathologies. Finally, we will argue how targeting the epithelium is emerging as a novel therapeutic strategy that holds promise for addressing these chronic diseases.
上皮组织是一个动态屏障，该上皮层的损伤控制着各种复杂机制，不仅涉及上皮细胞，还包括所有驻留组织成分，包括免疫细胞和基质细胞。传统上，以上皮组织受损为特征的疾病被视为“免疫性疾病”，旨在预防和治疗这些疾病的研究主要集中在以免疫为中心的治疗策略上，但这些策略往往无法阻止或逆转疾病的自然进程。在本综述中，我们打算聚焦于由上皮组织驱动的确保屏障功能的特定机制。我们将把哮喘和炎症性肠病作为重点，因为我们认为这两种疾病是上皮组织源性病理的相关实例。最后，我们将论证靶向作用于上皮组织如何正在成为一种有望解决这些慢性疾病的新型治疗策略。
